HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Antimelanoma effect of 4-S-cysteaminylcatechol, an activated form of 4-S-cysteaminylphenol.

Abstract
Rational chemotherapy of malignant melanoma could be developed by taking advantage of the presence of melanogenic enzymes in melanoma cells. 4-S-Cysteaminylphenol (4-S-CAP) has been evaluated for melanocytotoxicity and antimelanoma effect. Although 4-S-CAP is selectively toxic to pigmented melanoma cells, it is not potent enough when applied as a single agent. To increase the efficacy of 4-S-CAP, we synthesized 4-S-cysteaminylcatechol (4-S-CAC), an activated form of 4-S-CAP, and compared its biochemical properties and antimelanoma effects with those of the isomers 3-S-cysteaminylcatechol (3-S-CAC) and 2-S-cysteaminyl-hydroquinone (2-S-CAH). 4-S-CAC was found to be a better substrate for melanoma tyrosinase than was L-3,4-dihydroxyphenylalanine, the natural catecholic substrate. 3-S-CAC was a poor substrate, whereas 2-S-CAH was not a substrate. 4-S-CAC was the most cytotoxic to three lines of melanoma cells in vitro, followed by 2-S-CAH and 3-S-CAC. When applied i.p. for 9 days at a dose of 100 mg/kg, 4-S-CAC.HCl, increased by 46-52% the life span of C57BL/6 mice inoculated i.p. with B16 melanoma; this effect was comparable to that of a 50 mg/kg dose of 5-(3,3-dimethyltriazenyl)-1H-imidazole-4-carboxamide. 3-S-CAC was marginally effective, whereas 2-S-CAH was toxic to the host. This systemic toxicity of 2-S-CAH reflected its susceptibility to autoxidation. Growth of B16 melanoma cells inoculated s.c. was significantly inhibited by i.p. administration of 4-S-CAC.HCl (200 mg/kg) for 5 days (P < 0.05). These results suggest that 4-S-CAC is a potent antimelanoma agent, the effect of which is mostly mediated through tyrosinase oxidation.
AuthorsS Inoue, K Hasegawa, S Ito, H Ozeki, F Solano, C Jiménez-Cervantes, K Wakamatsu, K Fujita
JournalCancer research (Cancer Res) Vol. 55 Issue 12 Pg. 2603-7 (Jun 15 1995) ISSN: 0008-5472 [Print] United States
PMID7780975 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • 4-S-cysteaminylcatechol
  • Antineoplastic Agents
  • Membrane Glycoproteins
  • Proteins
  • Levodopa
  • Cysteamine
  • Oxidoreductases
  • TYRP1 protein, human
  • Tyrp1 protein, mouse
  • tyrosinase-related protein-1
  • Monophenol Monooxygenase
  • 4-S-cysteaminylphenol
Topics
  • Animals
  • Antineoplastic Agents (pharmacology, therapeutic use)
  • Biotransformation
  • Cell Division (drug effects)
  • Cell Line
  • Cell Survival (drug effects)
  • Cysteamine (analogs & derivatives, metabolism, pharmacology, therapeutic use)
  • Dose-Response Relationship, Drug
  • Humans
  • Kinetics
  • Levodopa (pharmacology)
  • Melanoma (metabolism, pathology)
  • Melanoma, Experimental (drug therapy, pathology)
  • Membrane Glycoproteins
  • Mice
  • Mice, Inbred C57BL
  • Mice, Inbred DBA
  • Monophenol Monooxygenase (metabolism)
  • Oxidation-Reduction
  • Oxidoreductases
  • Proteins (metabolism)
  • Tumor Cells, Cultured

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: